Skip to main content
Premium Trial:

Request an Annual Quote

GenomeDx Signs Deals with Three PPOs

NEW YORK (GenomeWeb News) – Molecular Diagnostics firm GenomeDx said today it has entered into agreements to provide laboratory testing as a participating provider with three preferred provider networks.

The PPOs are Stratose, Three Rivers Provider network, and Fortified Provider Network. The deals expand the number of covered lives with access to GenomeDx's Decipher prostate cancer classifier test by 62.6 million, the San Diego-based firm said.

The Decipher test analyzes whole genomes to profile RNA expression signatures. It measures the aggressiveness of prostate cancer in patients who have had a prostatectomy and classifies a patient's risk of disease progression, metastasis, and prostate-related death after a prostatectomy.

"We are focusing on providing access to patients who can benefit from the Decipher test, which offers physicians and their patients actionable information from which to make informed decisions about the course of treatment after prostate surgery," GenomeDx CEO Doug Dolginow said in a statement. "These agreements represent just the beginning of our efforts to engage payors."

GenomeDx closed a Series B financing round in late September for an undisclosed amount.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.